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1. Introduction 
1.1 Clinical aspects of Glioblastoma (incidence, diagnosis, treatment) 
1.1.1   Incidence 
 
Among all cancers, glioblastoma multiforme (GBM) is the most frequent and most 
malignant human brain tumor. GBMs are very aggressive, highly invasive as well as 
neurologically destructive. They are considered to be among the deadliest of human 
cancers, with median survival from 9 to 12 months on average. GBMtypically 
originates in the cerebral hemisphere of patients between 50 and 70 years of age 
from a differentiated astrocyte or brain tumor-initiating cell (BTIC), preferably within 
the white matter of the frontal, temporal, or parietal lobe. Of the estimated 2000-3000 
primary brain tumors diagnosed in Germany each year, approximately 70% are 
GBM. The incidence for GBM is therefore 5 cases per 100000 patients [1,2]. 
Glioblastomas are divided into two subclasses based on clinical characteristics: 
primary and secondary GBMs. Primary GBMs, found more frequently in older 
patients, are very aggressive and highly invasive. They arise from a de novo process, 
in the absence of a preexisting low-grade lesion. Secondary GBMs are usually 
observed in younger patients and develop progressively from low-grade astrocytoma 
over a period of 5 to 10 years [3]. 
The World Health Organization (WHO) grading system classifies gliomas into grade I 
to IV based on their degree of malignancy, as determined by histopathological criteria 
[4]. Table 1 displays examples and the criteria according to the WHO classification 
system. In the year 2016 a new WHO grading system will be introduced but is not 
available by the time of writing. In the central nervous system grade I gliomas 
generally originate in a benign way, are circumscribed, median survival is higher and 
curative approaches are possible. Grade II-IV gliomas are malignant and diffusely 
infiltrate throughout the brain making a curative approach often impossible. 
Astrocytomas are the most common CNS neoplasms, representing more than 60% 
of all primary brain tumors. They vary from grade II to III. Glioblastoma multiforme is 
the most malignant form of infiltrating astrocytoma and is classified as grade IV 
astrocytoma.It is known to be one of the most aggressive human cancers. 
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Table1: The World Health Organization (WHO) grading system for astrocytoma (adapted from [4]) 
WHO-Grade Example Criteria 
WHO-Grade I Pilocytic astrocytoma, 
Ependymoma/Subependymoma 
Low proliferating, 
discrete, non-invasive 
character 
WHO-Grade II Diffuse astrocytoma, papillary-, cellular- and 
clear cell ependymoma 
Modestly proliferating, 
partly invasive 
character 
WHO-Grade III Anaplastic astorcyoma/ Anaplastic 
ependymoma 
Fast proliferating, 
invasive character  
WHO-Grade IV Glioblastoma multiforme, Medulloblastoma, 
highly malignant glioma-like Pineoblastoma 
Rapidly proliferating, 
highly invasive 
character, necrosis  
 
 
1.1.2  Diagnosis 
 
Along with a history of present disease and a neurological examination the 
radiographic appearance is the first evidence of a glioblastoma burden. GBMs are 
known for rapid cell turnover, which leads to an insufficient vascular supply.The 
typical radiographic correlation to this fact is a ring-enhanced lesion with a necrotic 
core, a large amount of vasogenic edema and a mass effect in the appearance on 
MRI. In the CT scan, GBM impresses as a space-occupying lesion with an irregular 
hypodense center representing necrosis.It can present witha midline shift or a 
compression of ventricles. In the T1 section,glioblastoma presents as a hypo- to 
isointense mass within the white matter containing a central heterogeneous signal 
representing necrosis and intratumoral hemorrhage. The enhancement is variable, 
typically peripheral and irregular. In the T2 and FLAIR section, the tumor shows a 
hyperintense mass surrounded by vasogenic edema. PET scans can show an 
accumulation of FDG (representing increased glucose metabolism), which typically is 
greater in the tumor than in the physiological metabolism of the gray matter. The 
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typical radiographic appearance of a left frontal glioblastoma in the different 
sequences is shown in Figure 1. 
 
 
 
 
 
 
 
The differential diagnosis for a ring-enhanced lesion on MRI includes besides tumor: 
abscess, metastasis, brain lymphoma, demyelination and subacute ischemia. 
Therefore a definitive diagnosis of a suspected GBM on a CT or MRI scan can be 
proven only by a stereotactic biopsy or craniotomy with tumor resection followed by a 
histopathological examination. After the neuropathological diagnosis, thepatient‘s 
treatment can be initiated. 
Surgery in malignant glioma patients commonly aims at removing as much of the 
tumor as possible without causing new neurological deficits in the patient. Biopsy 
may be the only option for multifocal tumors, tumors involving the corpus callosum or 
other eloquent regions. Although a total resection cannot be achieved in glioma 
surgery at present, the benefits of a glioma surgery contain: symptomatic relief from 
a mass effect and obstructed cerebrospinal fluid (CSF) circulation. After surgical 
relief of local compression, global symptoms such as headache, nausea and 
vomiting can improve along with a reversal of neurological deficits [6]. Another 
benefit of aggressive surgical resection is the reduction in the amount of neoplastic 
cells.A lower tumor load increases the efficacy of adjuvant therapy [7]. A further profit 
of a neurosurgical intervention is the more accurate diagnosis. The accuracy of 
histological diagnosis is dependent on the size of the tissue sample. False negative 
diagnosis is often related to a stereotactic biopsy as a result of limited tissue 
Figure 1: MRT-morphology of left frontal GBM: (adapted from [5]) A: Axial view shows a hypointense 
lesion B: T1 post contrast image with irregular enhancement. C: T2 FLAIR images show increase in 
FLAIR signal. D: T2 FSE images also demonstrate increase in signal 
  1. Introduction   
9 
 
samples[8]. Another notable benefit is the collection of human tumor samples for 
research analysis such as has been performed for this thesis.  
In order to maximize the removal of pathological tissue with the minimum post-
operative functional deficit the pre-operative knowledge of the proximity of the 
pathological tissue to the eloquent cortex is of fundamental importance for accurate 
and safe neurosurgical planning. Functional MRI provides information regarding 
anatomical variations, as well as a tumor related shift of functional cortical centers. 
Recently, the use of 5-ALA(5-Aminolevulinic acid)was established in glioma surgery. 
5-ALA induces the accumulation of fluorescent porphyrins selectively in glioma cells. 
The dye is orally applied in a dosage of 20mg/Kg 5 hours prior to surgery. During 
operation the tumor can be visualized under dark light condition.More complete 
resections can be achieved which prolongs patients survival [9]. However, a 
complete tumor resection (R=0) can not be guaranteed and chemotherapy is part of 
the treatment protocol. 
 
1.1.3  Treatment 
 
The current treatment for newly diagnosed GBM includes surgical resection, followed 
by radio-chemotherapy with temozolomide (TMZ). This is based on the investigation 
of the European Organization for Research and Treatment of Cancer (EORTC) and 
the National Cancer Institute of Canada (NCIC).In 2009, Stupp et al designed a large 
multicenter phase III trial to compare the concurrent use of temozolomide and 
radiation therapy versus radiation therapy alone in patients with histologically 
confirmed newly diagnosed glioblastoma. The final analysis included a median 
follow-up of 61 months. Progression-free survival in the treatment group was 11.2% 
at 2 years, 6% at 3 years, 5.6% at 4 years, and 4.1% at 5 years. For patients treated 
with radiation alone, the progression-free survival was 1.8% at 2 years and 1.3% at 
3, 4, and 5 years [10] (Figure 2). 
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Particularly important in glioblastoma is the methylation status of MGMT (O-6-
methylguanine-DNAmethyltransferase), which is a predictive factor for therapy 
response and the survival of glioblastoma patients treated with temozolomide (TMZ) 
and radiation therapy (RT). MGMT methylation has been observed in about 35% of 
primary glioblastomas [11]. The methylation status of MGMT is a positive prognostic 
marker.It is frequently used as a diagnostic tool. TMZ and other alkylating agents 
modify the O6-position in guanines thereby forming critical DNA lesions that progress 
to lethal DNA cross-links, which prohibit cell replication. The DNA repair enzyme 
MGMT is able to remove alkyl groups, thus introducing resistance to TMZ treatment. 
When the promoter of MGMT is methylated, MGMT is not transcribed and therefore 
cannot repair DNA damage caused by TMZ making TMZ more efficient and 
prolonging overall survival. The mechanism is displayed in Figure 3.  
 
 
 
 
 
 
Figure 2: Kaplan-Maier estimates of 
overall survival by treatment group 
(adapted from [10]). 
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Patients with a methylated MGMT promoter show a partial response to 
chemotherapy, and the over all survival is higher when compared to patients with 
unmethylated tumors. The lack of MGMT methylation is associated with a much 
higher risk of death and a lower over all survival [10].However, the methylation 
statusof the MGMT promoter is a better predictive factor of outcome 
afterchemotherapy treatment than the grade of the tumor, the Karnofsky performance 
status or the patient‘s age. Kaplan-Meier curve in Figure 4 displays the difference for 
overall survival according to MGMT promoter methylation [10]. 
 
 
Figure 3: MGMT is inhibiting temozolomide therapy (adapted from [12]) 
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1.2.       Immune System  
1.2.1   Basics of the human immune system (innate/acquired)  
 
The physiological task of the human immune system is the recognition and defense 
of harmful pathogens. The classical concept of the immune system distinguishes 
between innate and acquired immunity. Both forms contain cellular and humoral 
components, which are described as follows:  
Characteristic for innate immunity is a general reaction against a wide spectrum of 
genetically conserved pathogens, an inability to modify the evolutionary preserved 
function and a full reactivity at the first contact with an antigen without previous 
sensitization. The cellular spectrum of the innate immunity consists of granulocytes 
and the monocyte-macrophage system, whereas the humoral spectrum contains a 
multitude of proteins, which are found in blood and other body fluids and can defend 
the organism without cellular components. Examples of these proteins arelysozyme, 
defensin, mannan-binding lectin, c-reactive protein, LPS-binding protein as well as a 
group of proteins of the complement system. The basic mechanism of action is the 
recognition of certain patterns which are common in several pathogens, but are 
absent on human cells.  A good example for this pathogenic pattern is the 
lipopolysaccharide (LPS), which is a part of the gram-negative bacterial cell wall. 
Granulocytes, specially neutrophilic granulocytes are circulating in a large cell 
amount in the blood-system.They are migrating, mediated by chemotactic mediators 
Figure 4: Overall survival according to MGMT promoter methylation in combined radiochemo therapy vs 
radiotherapy alone. A:Patients with methylated MGMT promoter. B: Patients with unmethylated MGMT 
promoter (adapted from [10]) 
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and activated endothelia, into the locus of tissue damage. Granulocytes are loaded 
with a diverse amount of lytic enzymes in their intracellular granula, which give them 
the ability to lyse cellular debris and pathogens after phagocytosis. This fast 
appearing first immune reaction is responsible for the stereotypical clinical 
presentation of inflammation: rubor, calor, dolor, and pus (as a result of degenerated 
granulocytes) as well as blood-neutrophilia. The granulocytic inflammation can be 
enhanced via the mechanism of opsonization (pathogen marking for phagocytosis) 
through the humoral component of the innate immune system, namely by 
opsonization with proteins of the complement system and the recognition through the 
granulocytic complement-receptors, as well as through the humoral acquired part of 
the immune system, namely opsonization with specific immunoglobulins and their 
recognition through granulocytic Fc-receptors.  
Contrary to the enormous amount of circulating, short-lived granulocytes, cells of  the 
monocyte-macrophage system are present in a smaller amount of circulating or 
tissue resident long-living cells which are equipped with related capabilities, but still 
differ in important topics. Analogous to the granulocytes, macrophages can recognize 
antigen-patterns and phagocyte/lyse infected structures through their membrane-
bound receptors such as CD14 molecules, scavenger-receptors, mannose-receptors, 
complement-receptors and toll-like-receptors (TLR). An important role of the immune 
reaction of these cells is the activation of the acquired immune system, namely the 
lymphocytes. This is maintained via two main mechanisms. On the one hand, the 
secretion of tumor necrose-factor alpha (TNFα) and interleukin 8 (IL-8) modulates the 
permeability of the vessel-endothelia which enables the invasion of plasma-proteins 
into the inflammatory tissue region. Further the endothelia-modulation leads to 
restriction of the leucocytes (rolling) and facilitates the penetration of leucocytes 
through the vessel (extravasation), which leads to an accumulation of effector cells in 
the inflammatory region. On the other hand, macrophages secrete IL-6 and IL-1, 
which stimulates the liver to produce acute-phase-proteins (e.g. c-reactive-protein) 
and respectively leads to an increase of body temperature. Taken together, these 
mechanisms create a pro-inflammatory setting, which itself will induce further 
immunologic reactions described next [13]. 
Characteristic for the acquired or adaptive immune system is the creation of an 
immunologic memory, which will allow the organism to react faster and more 
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intensely, in the case of repeated exposure to a certain pathogen. The acquired 
immune system is therefore a tool which can be sensitized after a first time pathogen 
contact or in an iatrogenic manner such as vaccination. The cellular compound of the 
acquired immune system consists of lymphocytes, which can be further subdivided 
into T-cells and B-cells. Immunoglobulins, (e.g. IgG) which are secreted by the B-
cells or respectively their activated form the plasma B cells, form the humoral 
compound of the acquired immunity.  
T- and B- Cells provide a pool of resting cells which differs in the preformed antigen-
specificity of their surface receptors. As a basic functional concept, T- and B-cells are 
activated according to their antigen-specificity after exposure of the body to the 
specific antigen in a phase called the initiation phase. Resting T-cells (T-helper cells 
or cytotoxic T-cells) are activated through dendritic cells, resting B-Cells are activated 
by T-effectorcells.Respectively, the clonal expansion of these activated cells and 
their differentiation into effector cells lead to a specific immune-reaction against the 
corresponding antigen in a phase called effector phase.    
In the case of T-cells, the main effect is a lysis of target cells through cytotoxic T-cells 
(CTL). The transformation from resting B-cells to activated plasma-B-cells will 
respectively  lead to synthesis and release of specific immunoglobulines with the 
effect of opsonization of the target pathogen. Whereas the first antigen contact will 
take a long response time of the previously described signal pathway, a second 
exposure will lead to a much faster immunologic reaction. This can be achieved by 
the generation of memory-T- and B-cells, which will remain as a immunological 
memory after a healed up tissue damage or infection. The amount of cells containing 
antigen specific surface-receptors remains hereby elevated. Moreover the activation 
of memory cells is easier and more effectively achieved as for example naïve T-cells 
can be activated only via dendritic cells whereas memory-T-cells can be activated 
through every kind of antigen presenting cell (APC).  
1.2.1   Antigen-presentation and the major histocompatibility complex 
 
The function of the acquired immune system is based on the cleavage of 
endogenous as well as exogenous proteins into peptides (antigen processing) and 
their following presentation on the cell surface (antigen presentation). This processes 
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takes place in almost all human cells, although there is a difference between 
nucleated cells and the APCs. 
In almost all nucleated cells, within the scope of cytosolic protein transport of the 
antigen proceeding, endogenous proteins or proteins of intracellular pathogens 
(virus, chlamydia, toxoplasmosis) are cleaved in the proteasome into peptides. These 
peptides are transferred in a ATP-dependant manner into the endoplasmic reticulum, 
where the peptides are associated with the major histocompatibility class I-proteins 
(MHC-class I proteins) and carried to the cell membrane from where they can be 
recognized by cytotoxic T-cells. In specialized antigen presenting cells such as 
dendritic cells (DC) and microglia,extern proteins can be ingested via phagocytosisor 
receptor mediated endocytosis. The potentially harmful proteins can further be 
processed for antigen presentation. After intracellular cleavage in the lysosome, the 
resulting peptides are associated with MHC-class II proteins for cell membrane 
associated presentation. T-helper cells can recognize the presentation and induce 
target specific cytotoxic immune response.  
 
1.2.3  T-cells 
 
Within the T-lymphopoesis, multi potent lymphatic stem-cells from the bone marrow 
undergo an important phase of their development in the thymus. The thymus is the 
organ where through the mechanism of positive selection auto-reactivity of T-cells is 
prevented. Only T-cells which recognize the body own MHC-proteins are selected for 
further proceedings. The second step is known as a negative selection. Autoreactive 
T-cells and lymphocytes which show a reactivity against body own peptides are 
eliminated through induced apoptosis [13]. 
Due to this mechanism, the body creates a T-cell contingent which can identify 
exogenous peptides that are presented in association with MHC-proteins, whereas 
auto-antigens under physiological circumstances are recognized as endogenous and 
are exempt from an immune reaction. With the assistance of flow cytometry analysis, 
T-cells in general can be described as CD3+ cells within the CD45+ leucocyte 
population. A further characteristic feature of T-cells is the expression of a T-cell-
receptor (TCR), which shows in analogy with the immunoglobulin‘s a variable 
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antigen-specific region. A further subdivision of CD45+ CD3+ cells can be achieved 
with the surfacemarkers CD4, CD8 and CD25. According to this, T-cells located in 
the human immune system can be subdivided as follows: 
CD45+ CD3+ CD4+ : This subgroup consists of T-helper-cells (Th-Cells), which can 
recognize peptides presented on the MHC-class II proteins and after activation 
through antigen presenting cells (APC) can take several further differentiations: 
-TH1-Cells: As effector-cells, Th1-cells can recognize their specific peptide on 
dendritic cells (DC) and produce IL-2 along with interferon γ (IFN γ). They induce a 
cellular immune reaction through activation of macrophages and cytotoxic T-cells as 
well as the synthesis of opsonizating immunoglobulins (IgG and IgM).  
-Th2-Cells: As effectorcells, Th2-Cells recognize their specific peptide on B-cells, 
produce IL-4 and via B-cell activation, induce a humoral immunologic reaction 
including the synthesis of all kinds of immunoglobulins as well as the activation of 
eosinophilic granulocytes and mastcells, B-cell activation and 
plasmacelldifferentiation  
-Th3-Cells: This subpopulation of T-cells produce IL-10 and transforming growth 
factor  β (TGF β) and cause negative regulatory effect on the immune response.  
-CD45+ CD3+ CD8+: These cytotoxic T-cells (CTL), recognize peptides presented on   
MHC-class I proteins, and after being activated induce the apoptosis of the 
presenting cell through secreting perforin, granzymes and FasL.  
-CD45+ CD3+ CD4+ CD25+: This subgroup is termed regulatory T-cells (Treg). Tregs, 
after being activated through their specific TCR, can initiate a suppression of the 
immunologic response of all other T-cellsubtypes. Their role is essential for 
maintaining peripheral tolerance, preventing autoimmune diseases and limiting 
chronic inflammatory diseases. As a negative result, their presence seems to limit the 
anti-tumor immunity. According to the flow cytometric analysis of surface markers, 
Treg express continually the transcriptionfactor FoxP3, which is seen as a specific 
marker for Treg [14]. The absence of the CD127 marker on CD4+ CD25+ cells 
defines the characteristic of this subpopulation, as the correlation of the absence of 
CD127 and the presence of FoxP3 on Tregs is over 90% [12]. The mechanism of 
immunosuppression by Tregs is not fully understood, but includes amino acid 
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depletion, cytokine secretion (TGF-ß, IL-10) and direct cell-cell inhibition leading to a 
local immunosuppressive environment (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.4   The Immune System in the CNS  
 
The immune system of the central nervous system was traditionally described as an 
organ with „immune privilege―, stating that the immune reaction against antigens is 
less effective than in other tissues of the human body [16, 17]. The main reason is 
the unimpaired blood-brain-barrier that prevents the penetration of complement-
factors, immunoglobulins and circulating inactivated immune cells into the brain. The 
strict description of the brain as an immunologically impaired organ was recently 
questioned with the identification of a slight number of T-cells in the healthy brain 
[18], a lymphatic drainage into the cervical lymph nodes [19] and an intrathecal 
expression of antibodies with an intact blood-brain-barrier [20]. Whereas the 
description of the CNS as a location of „immune privilege― may apply within healthy 
Figure 5: Four basic principles of T-cell suppression through Tregs (adapted from [15]) 
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conditions, numerous diseases show humoral as well as cellular elements of the 
immune system in the CNS and liquor.Examples are cerebral infections, 
experimental autoimmune encephalitis (EAE), autoimmune diseases [21] and (within 
the case at hand) also brain tumors. Why primary brain tumors can exist in the CNS, 
whereas their metastases are mostly controlled by the immune system remains 
unclear. One can assume a potentiation of the previously described effects caused 
by the immunological conditions in the CNS as well as the escape-mechanisms of a 
tumor cell. 
 
1.2.5   Tumor immunology in GBM 
 
Although immune cells were found inside the GBM tumor site indicating an immune 
reaction of the host body against the tumor, the detailed mechanism and the reason 
for insufficiency in terms of tumor growth inhibition and elimination remain unclear. 
GBM seem to inhibit an anti-tumor immune response in the CNS by causing local 
and systemic immune-suppression through several hypothesized mechanisms [22].  
Considerations include the fact that in specimen of GBM patients, tumor-infiltrating 
lymphocytes (TIL‗s) were identified. Among them the presence of 
immunosuppressive T regulatory cells (Treg) was seen [23]. Another cell type that 
might contribute to the immunosuppressive microenvironment of malignant gliomas 
are myeloid-derived suppressor cells (MDSCs).These cells compromise a 
heterogeneous population of myeloid cells that were shown to be significantly 
expanded in cancer patients and are associated with tumor progression.  
 
1.3 Myeloid Derived Suppressor Cell's 
1.3.1  Characteristics 
 
In mice, MDSCs consist of a heterogeneous population of activated immature 
myeloid precursor cells that lead to immune suppression. They are known to 
accumulate in tissues of trauma patients, infectious disease, and septic conditions 
and were found to be present in bone marrow, liver, spleen, and tumor. In mice, 
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MDSCs were characterized throughtheir marker profile of CD11b, CD33 and GR1, 
but the lack of the mature myeloid marker HLA-DR. The granulocytic marker GR1 
includes both isoforms of Ly6C and Ly6G. Furthermore, a distinction in mice MDSCS 
was made between monocytic MDSCs (CD11b+Ly6G-Ly6Chigh), and granulocytic 
MDSCs (CD11b+Ly6G+Ly6Clow) subtypes [24]. Both subtypes can suppress T cell 
function by the production of Arginase that decreases the level of L-arginine, which is 
critical for normal T cell function.Reduced levels of Arginine are known to reduce T 
cell receptor chain expression and to promote T cell dysfunction.MDSCs cells further 
have the property to secrete nitric oxide and reactiveoxygen species, which are 
capable of inducing T cell suppression [25]. However tumor-free mice were found to 
contain the same phenotype of MDSCs in their peripheral blood system and 
lymphatic organs although in a much lower quantity. Tumor-associated MDSCs are 
believed to arise from immature myeloid progenitors through abnormal differentiation, 
which is promoted by factors in the tumor environment. Recruitment of MDSCs to the 
tumor site is regulated through cytokines and growth factors, such as granulocyte 
macrophage colony stimulating factor (GM-CSF), granulocyte colony-stimulating 
factor (G-CSF), interleukin (IL)-2, and vascular endothelial growth factor (VEGF) [26].  
In humans, MDSCs were found in patients with solid and lymphatic tumor burden as 
well as in trauma and sepsis. The amount of isolated MDSCs in tumor patients was 
found to positively correlate with the tumor progression and metastasis. In contrast to 
MDCSs in mice, human MDSCs lack the GR1 marker and were therefore 
characterized by the monocyte/macrophage marker CD11b, the monocyte 
differentiation antigen CD14, the mature monocyte marker CD15, the myeloid lineage 
markers CD33, and the absence of HLA-DR, which is commonly expressed on 
myeloid cells. Therefore, a significant number of different phenotypes have been 
documented in tumors of different origins. Previously, it could be demonstrated that 
patients with newly diagnosed glioblastoma have an increased number of circulating 
CD33+ HLA-DR- MDSCs in their blood that are composed of neutrophilic (CD15+), 
immature (CD15-CD14-), and monocytic (CD14+) subsets [27, 28].Since none of the 
individual markers are unique to MDSCs, definitive identification of MDSCs was 
desired. MDSC antigens in humans and their known function that was used for the 
identification of human MDSC subsets in this thesis are listed below: 
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CD45 (PTPRC; Protein tyrosine phosphatase, receptor type c) is a single chain 
transmembrane receptor with intrinsic tyrosin phosphatase activity expressed 
exclusively on hematolymphoid cell membranes. It is counted to be an essential 
regulator of T and B cell antigen receptor-mediated activation. The disruption of its 
tyrosine kinase and phosphatase activity is a common trait in hematological 
malignancies[29]. 
CD14 is expressed mainly by macrophages, it  acts as a co-receptor (along with the 
Toll-like receptor (TLR 4) and MD2) for the detection of bacterial lipopolysaccharide 
(LPS). Binding of antibody to CD14 does not trigger signal transduction since CD14 
lacks a cytoplasmatic domain and therefore needs thethe presence of 
lipopolysaccharide-binding protein (LBP) to maintain its action. 
CD15 (also called Lewis X)is a ligand for selectins and might be involved in cell 
adhesion through a direct CD15-CD15 interaction. CD15 is expressed mainly on 
mature granulocytes and monocytes but also on immature bone marrow cells [30]. 
CD15 mediates phagocytosis and chemotaxis, is found on neutrophils and plays a 
key role in the diagnosis of Hodgkin‘s disease as it is found on almost all Reed-
Sternberg-cells. 
CD11b (Integrin alpha M) is a protein that mediates inflammation by regulating 
leukocyte adhesion and migration it is involved in several immune processes such as 
phagocytosis, cell-mediated cytotoxicity, chemotaxis and cellular activation. CD11b is 
expressed on the surface of many leukocytes (monocytes, granulocytes, 
macrophages, and natural killer cells). 
HLA-DR is an MHC class II cell surface receptor which presents (together with its 
intracellular digested ligand (antigen)) pathogens of foreign origin to the T-Cell 
receptors (TCR) on CD 4 / 8 T-cells, leading to their activation and differentiation into 
T-helper (CD4) and cytotoxic (CD8) T cells. 
CD16 (FcγRIII) is expressed as a transmembrane protein on the surface of NK cells, 
activated monocytes and macrophages. CD16 binds aggregated IgG or IgG-antigen 
complex which functions in NK cell activation, phagocytosis, and antibody-dependent 
cell-mediated cytotoxicity (ADCC). 
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CD124 (IL-4R alpha chain) can bind  and interact with IL-4 and consists of two types. 
The type I IL-4 receptor is present on T-, B-, NK, mast cells, basophils, and 
macrophages, whereas the type II IL-4 receptor is found mainly on non-
hematopoietic cells and macrophages. IL-4 is responsible for the generation of IgE 
antibodies and for propagating the differentiation of naive Th0 cells into Th2 cells. In 
mucosal barriers, the IL-4 is involved in the recruitment of innate and adaptive 
immune effector cells. 
1.3.2  Situation in different tumor entities 
 
Oncological studies in humans have reported an increased frequency as well as 
immunosuppressive activity in some of the myeloid-derived subsets present in 
peripheral blood of patients with cancer [31, 32]. The accumulation of immature 
myeloid cells (IMCs) Lin (CD3/CD19/CD56/CD14/CD16) CD33+ HLA-DR-/low in the 
blood correlates with the tumor burden as well as with the stage of the disease in two 
independent studies including a diverse set of cancer types [33]. Additionally, the 
frequency of either monocytic (CD11b+ CD14high CD15positive) or granulocytic (CD11b+ 
CD14lowCD15positive) myeloid derived cells with immune-suppressive function have 
been found to be increased in patients with renal cell carcinoma [34], HCC [35], 
NSCLC [36], gastrointestinal [37], and prostate cancer [38]. Overviews of known 
oncological diseases with different MDSC subsets are displayed in Figure 6. 
 
 
Figure 6: Presence of myeloid derived suppressor cells in human diseases (adapted from [31]) 
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2. Aim of this thesis 
 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of 
myeloid cells that are significantly increased in cancer patients and are associated 
with tumor progression and poor overall survival. There is also a large body of 
evidence that the phenotype and function of MDSCs are largely dependent on the 
tumor type and specific conditions within the tumor microenvironment. MDSCs can 
suppress T-cell responses by several mechanisms including the depletion of specific 
amino acids such as L-arginine that are essential for T-cell function, and increased 
production of reactive oxygen species (ROS) (Figure 7). Furthermore, MDSCs 
suppression mechanismsinclude the ability of promoting de novo T-regulatory cell 
development. So far, themajor difficulty in defining different human MDSC 
populations is that a specific marker is lacking. 
The purpose of this thesis was to investigate the frequency and phenotype of MDSCs 
through a fluorescent activated cell sorter (FACS) as well as to investigate the 
function of myeloid-derived cells (MDSCs) in peripheral blood and freshly resected 
tumor samples in a cohort of 52 GBM patients. The aim was to characterise, analyse 
and correlate these findings with clinical presentation in the pursuit of a better 
understanding of the complex mechanisms involved in the tumor immunology of 
glioblastoma. 
 
Figure7: Mechanisms of MDSC mediated immune suppression. (adapted from [39]) 
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3.Material and Methods 
3.1 Material 
3.1.1  Disposable materials 
 
Table2: Disposable materials 
Material  Order number Company 
Cell Culture Flask 25cm2 (red 
cap) 
83.1819.002 Sarstedt 
6-well plate 83.392 Sarstedt 
96-well plate 82.1581 Sarstedt 
50 ml syringe Original-Perfusor®       Braun 
Butterfly needle Sterican® Braun 
Petri dishes (145x20 mm 
sterile) 
PP14 A.HartensteinLaborbedarf 
Pipette Tips, white (10 µl) T-300  Axygen, by Abimed 
Pipette Tips, yellow (200  µl)  70.760.002 Sarsted 
Pipette Tips, blue ( 1000 µ) T-1000-B Axygen, by Abimed 
Scalpel 147222 Megro 
Pasteur Pipettes PP07  A.Hartenstein Laborbedarf 
15 ml falcon tube  SS-3205 Sarsted 
50 ml falcon tube SS-7004 Sarsted 
 
3.1.2   Chemicals and reagents 
 
Table3: Chemicals and reagents 
Material  Order number Company 
Lymphoprep 1,077g/cm3 1114544 Axis-Shield 
BiochromPBS Buffer (10x 
Dulbecco‘s) 
A0965 AppliChem 
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DMSO F-518 Finnzymes 
EDTA E5134 Sigma-Aldrich 
Ethanol 99.8 % 9065.2 Carl-Roth 
Glycerin Solution (for 
microscopy) 
11513872 Leica 
Glycerol 3783.1  Carl-Roth 
Glycine G7126 Sigma-Aldrich 
Immersion Oil  11513859 Leica 
Isopropanol A0900 AppliChem 
Paraformaldehyde 0335.1  Carl-Roth 
PMA      P8139-1MG Sigma-Aldrich 
Ionomycin I9657-1MG Sigma-Aldrich 
 
3.1.3   Kits 
 
Table4: Kits 
Kit Order number Company 
Pan T-cell isolation kit   130-096-535 Miltenyi Biotec 
Permeabilization Kit 88-8824-00 eBioscience 
 
3.1.4   Media, reagents and supplements for cell culture 
 
Table5: Media, reagents and supplements for cell culture 
Media  Order number Company 
Dulbecco‘s Phosphate Buffered 
Saline 
14190094 Invitrogen, Gibco 
HBSS Ca2+/Mg2+ 14025050 Invitrogen, Gibco 
Fetal Bovine Serum SH30109.03 Thermo Scientific 
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RPMI 1640 Lifetechnologies 
Fetal calf serum 26010074 Gibco, Invitrogen 
Collagenase type IA C0130 Sigma-Aldrich 
DNAse type I D4527 Sigma-Aldrich 
Trypsin-Inhibitor type I-S T1021 Sigma-Aldrich 
Propidiumiodide P4170-10MG Sigma-Aldrich 
CFSE                                                               21888-25MG-F                       Sigma-Aldrich 
DCFDA D-399 Lifetechnologies 
Brefeldin A 20350-15-6 Sigma-Aldrich 
Penicillin-Streptomycin-
Glutamine (100X)     
10378-016 Thermo Scientific 
1X permeabilization buffer 00-8333-56 eBioscience 
Fixation/Permeabilization 
Diluent 
00-5223-56 eBioscience 
 
3.1.5   Antibodies 
 
Table6: Antibodies 
Antibodies   Order number Company 
CO-conjugated anti-CD45 17-9459 eBioscience 
PE-Cy5.5–conjugated anti-
CD14 
11-1469 eBioscience 
PB-conjugated anti-CD15 46-0158 eBioscience 
PE-Cy5.5–conjugated 
antiCD11b 
IM0530U Beckman Coulter 
Alexa-750–conjugated anti-
CD16 
56-0168           eBioscience 
ECD-conjugated  anti-HLADR 11-9952 eBioscience 
PE-conjugated anti-CD124 14-1249          eBioscience 
  3.Material and Methods   
26 
 
I-FITC  anti-human Arginase IC5868P R&D Systems 
FITC anti-sheep-IgG1 NL012 R&D Systems 
APC-Alexafluor750  anti-CD3   A66329 Beckman Coulter 
APC-Allophycocyanin anti- 
CD33 
8017-0337 eBiosciences 
 
3.1.6.   Buffer 
 
Table7: Buffer 
Buffer Annotation  
Lyse-buffer Ammoniumchlorid-solution  
(8,3g/l NH4Cl, 1g/l KHCO3, 0,0375g/l EDTA) 
 
3.2  Methods 
 
3.2.1   Patients characteristics 
 
Tumor and blood specimens were collected from 52 patients with a median age 63.5 
years (range 41 - 82).Blood samples were also collected from 26 age and gender 
matched healthy donors with a  median age of 65,5 years (range 41-79) with no 
history of malignancies or autoimmune diseases and were enrolled in the study 
(Table 8). Written consent was obtained from all individuals before blood sampling 
and the ethical committee approved the study. 
 
3.2.2   Intraoperative CUSA assisted resection of GBM 
 
Glioma patients underwent 5-ALA assisted operation with general anesthesia, 
followed by craniotomy and tumor resection with the cavitron ultrasonic surgical 
aspirator (CUSA EXcel®). Tumorspecimenwere collected in the CUSA suction-bag 
thatultimatelycontained suspensions of single cells, tissue fragments, and blood in 
saline. The CUSA apparatus is used as a routine device in resections of brain tumors 
since its introduction by Flamm [40]. Compared with the small diagnostic-biopsy 
samples of brain tumors, ultrasonic surgical aspirations contain generous amounts of 
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tumor cells in large volumes of fluid. Through a computerized control unit, with 
settings for different amplitudes of ultrasonic waves and speeds of irrigation and 
aspiration, the ultrasonic apparatus is an efficient intraoperative device for brain 
tumor resection. Tumor tissues are targeted and selectively aspirated. An advantage 
of the ultrasonic aspiration technique over surgical tissue dissection is the reduced 
need for retraction of normal brain-tissue and a decreased injury of neurons and glia 
cells in the patient‘s brain. The aspirated contend was evacuated into a sterile pouch 
and sent to the laboratory, where the aspirated material was processed immediately 
(Figure 8). 
 
 
 
 
 
 
 
 
 
3.2.3  Isolation of tumor infiltrated leucocytes (TIL’s) from tumortissue 
 
Ultrasonic aspirates were collected in a closed system disposable suction bag. 
Tumor fragments were washed extensively with PBS to discard blood and suction 
fluid. Tumor fragments were cut into small pieces and incubated with Collagenase 
type IA (100 mg/mL), DNAse type I (10 µg/mL) and a trypsin inhibitor type I-S from 
Glycine max in HBSS with Ca2+ and Mg2+at 37°C. After 45 minutes, EDTA was 
added (12.5 mM final), the cell suspension prepared, filtered and transferred into a 
15 ml falcon tube. After sedimentation at 1g for 30 min, the supernatant was 
collected and loaded on a modified Ficoll gradient (75% Ficoll/25%RMPI supplement 
with 10% FCS). The interphase containing mainly myelin debris and dead cells was 
removed, and the pellet was immediately used for further analysis after washing.  
 
Figure 8: left: intraoperative view of Glioblastoma resection situs with the CUSA apparatus, right: 
laboratory setting before proceeding the specimen 
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3.2.4 Isolation of peripheral blood mononuclear cell’s (PBMC) from 
venous blood 
 
After a detailed medical clarification, the blood sample was withdrawn from a 
periphery vein. For isolation of the mononuclear cells, the density gradient 
centrifugation method was used. The venous blood was carefully underlayered with 
15ml Lymphoprep. After centrifugation with 740g without break at 20 °C for 20 
minutes, the mononuclear cells became visible in a solid layer between the 
Lymphoprep and the plasma supernatant, and could be rescued with a manual pipet 
and transferred into a 50ml falcon tube. In the following washing step the 
mononuclear cell containing falcon tube was filled up with cold PBS and again 
centrifuged at 500 g for 7 minutes at 4 °C. 25ml Lyse-buffer was added and 
resuspended with the gained cell sediment, thereafter incubated for 10 to 15 minutes 
on a shaking platform at 4 °C in order to lyse the remaining erythrocytes. 
Accordingly, the previously described washing step was repeated twice, and the cell 
sediment was thereafter resuspended in FCS and immediately used for further 
proceedings or conserved at 4°C over night. 
 
3.2.5   Fluorescent activated cell sorting (FACS) 
 
To determine the frequency and phenotype of MDSCs in freshly isolated PBMCs and 
tumor cell suspensions they were stained for 30 min at 4°C using a panel of directly 
labeled monoclonal antibodies (mAbs): CD124-PE (Phycoerythrin), HLADR-ECD  
(Phycoerythrin-Texas Red-X), CD14-PC5.5  (Phycoerythrin-Cyanin 5.5), CD11b-PC7 
(Phycoerythrin-Cyanin7), CD33-APC (Allophycocyanin), CD16-APC-Alexafluor750, 
CD15-PacificBlue,PE-Cy5-conjugated anti-CD3 and CD45-KromeOrange . Viability 
of CD45+ cells was checked by propidiumiodide and it usually was >95%. After 
washing, all samples were analyzed using the NaviosTM flow cytometer and the 
Kaluza 1.2 Software (Beckman Coulter, Germany).  
3.2.6   Cytospin preparation 
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A labeled slide, chamber and blotter for each sample was prepared and cells 
resuspended in HBSS containing 30% FCS to a concentration of approximately 
5x105 cells/ml. Next 200 µl of each cell suspension was added to a slide chamber 
and a spindown at 800 rpm for 5 minutes was performed.  The slide was carefully 
removed from the cytocentrifuge and cells were allowed to air dry prior to staining. 
 
3.2.7   ROS detection 
 
Oxidation-sensitive dye, dichlorodihydrofluorescein diacetate (DCFDA), was used to 
measure ROS production by MDSC. Cells were labeled with 1 μM DCFDA for 10 
minutes at 37 °C in PBS 1% FCS, washed twice and then incubated in complete 
medium (IMDM with L-glutamine containing 10% fetal calf serum, antibiotics 
(penicillin 100 U/mL, streptomycin 100 mg/mL)) for 30 minutes at 37°C. DCFDA-
labeled cells were then stained with MDSC surface antibodies as described above. 
After 30min incubation on ice, cells were washed twice with cold PBS and analyzed 
by color flow cytometry. Aliquots of Ab-stained cells which were not incubated with 
DCFDA served as controls.  
 
3.2.8   Arginase detection 
 
For intracellular Arginase I staining, the eBioscience Fixation/Permeabilization 
procedure was used. TILs and PBMCs obtained from GBM patients were washed 
and fixed by adding 100 µL of IC Fixation Buffer and pulse vortexing the cocktail. 
Next cells were incubated under dark conditions at RT for 40 minutes. 2mL of 1X 
permeabilization buffer was added and centrifugation of the samples at 400g for 5 
minutes was performed. The supernatant was discarded  and the previous step 
repeated.  The cells were resuspended in 100 µL of 1X Permeabilization Buffer and 
the I-FITC antibody was added and incubation for 40 minutes under dark condition at 
RT was performed. 2mL of 1X Permeabilization Buffer, added to the solution and the 
sample was centrifuged at 400g for 5 minutes under RT. The supernatant was 
discarded and 2mL of flow cytometry staining buffer was added. The washing step 
was repeated and the cells were resuspended in 5mL flow cytometry staining buffer 
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and analysed with the flow cytometer. Sheep IgG control Ab was used as negative 
control. 
 
3.2.9   MRI scans and tumor volume measurement 
 
All MRI examinations were performed with a 1.5-T clinical imaging system (Gyroscan 
Intera®; Philips Medical Systems, Best, The Netherlands) using a synergy head/neck 
coil. For volumetry contrast-enhanced axial and coronal or sagittal T1-weighted 
sequences were used. Tumor volume was calculated by the ellipsoid formula (4 x π x 
d1/2 x d2/2 x d3/2)/3 using the largest diameters in the axial plane and the largest 
diameter in the orthogonal plane.  
 
 
3.2.10  T-cell proliferation assay 
 
For T-cell proliferation assay, T cells were purified using a Pan T-cell isolation kit. 
Cells were resuspended in 40 µL of buffer and 10 µL of Pan T Cell Biotin-Antibody 
Cocktail was added. After vortexing cells were incubated for 5 minutes in the 
refrigerator at 6°C. Next 30 µL of buffer and 20 µL of Pan T Cell MicroBead Cocktail 
was mixed together and incubated for 10 more minutes at 6°C. Staining antibody 
anti-CD3 (10 µg/ml) was added and 5 more minutes of incubation under dark 
condition was performed. For magnetic separation MACS Column and MACS 
Separator were assembled according to manufacturers manual. The column was 
prepared by rinsing 3L of buffer. The cell suspension was applied onto the column 
and the unlabelled flow through representing the T-Cells  enriched fraction was 
collected into a 5mL tube. T-cells were next labeled with 1µM CFSE for 5 minutes in 
PBS containing 1% FCS, washed twice and seeded in a 96-well round-bottom plate 
coated with coated human anti-CD3 mAbs (10 µg/ml) at 5×104/well and were 
cocultured with MDSC-enriched subset cell ratios of 1/1 and 2/1 or 4/1 for 5 days at 
37°C in complete medium in the presence of 100 U/ml IL-2. T-cell proliferation was 
monitored by FACS analysis of CFSE fluorescence intensity after staining with PE-
Cy5-conjugated anti-CD3 mAbs. T-cells in culture medium alone were used as 
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background controls. Cocultures were conducted in triplicates. After 5 days, cells 
were harvested, stained with anti-CD3-PC5.5 and were analyzed by FACS.  
 
3.2.11  Intracellular INF- detection 
 
For intracellular IFN-γ detection, PBMC, TILs or CSFE-labeled T-cells were 
stimulated with phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, Germany; 100 
ng/mL) plus ionomycin (Sigma-Aldrich, Germany; 1 µg/mL) overnight (16 hours) in 
the presence of Brefeldin A (10 µg/ml). Cells were then stained with T-cell markers, 
further processed with the Fixation/Permabilization Kit from eBioscience, and labeled 
with a PE-conjugated IFN-γ mAb (Beckman Coulter, Germany). 
 
3.2.12  Statistic 
 
The data were analyzed with the Kolmogorov–Smirnov procedure to test for normal 
distribution. Since not all groups showed a normal distribution, the following non-
parametric tests were used: The two-tailed Mann-Whitney test was used to test for 
significant differences between two groups. The Kruskal–Wallis test with post hoc 
Dunn Multiple Comparison analysis was applied to test for significant differences 
between three and more groups. For correlation analysis, we used the Spearman 
rank test. Values of p<0.05 were considered to be significant. Error bars represent 
the SE of the mean. GraphPad Prism 5.0 (GraphPad Software Inc., USA) was used 
for statistical analyses. 
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4.Results 
4.1  Phenotype, morphology and frequency of different MDSC subsets in 
peripheral blood and tumor tissue of primary glioblastoma patients 
In order to analyze the different subsets of MDSCs in the peripheral blood and tumor 
tissue of primary glioblastoma patients, PBMCs obtained from the periphery blood 
and TILs obtained from the tumor specimen were enzymatically digested as 
described in the material and method section. MDSCs were gated from TIL and 
PBMC according to their CD45 antibody binding and CD11b positivity was further 
gated through PC7 antibody binding. CD11bpositive as well as CD45positive cells were 
then further gated according to their CD14 and CD15 marker expression. The gating 
strategy is shown in Figure 9. Cells expressing a low amount of CD14 were further 
split into CD15high, CD15negative and CD15intermediate subgroups. Cells showing a high 
CD14 expression were further subdivided into CD15high, CD15intermediate or 
CD15negative. 
 
 
A 
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B 
Figure9: Gating strategy for the assessment of the MDSC population from tumor infiltrating leucocytes 
and periphery blood mononuclear cells, using flow cytometry in GBM patients. A: Cells obtained from 
tumor tissue. B: Cells obtained from peripheral blood 
 
4.2. Patients characteristic n=52 
Table8:  Patients characteristic n=52 
Number of patients   52 (100%) 
   
Sex   
 male 33 (63%) 
 female 19 (37%) 
   
Median age years 63,5 (41-82) 
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Resection status   
 complete 25 (48%) 
 incomplete 27 (52%) 
   
Mean tumor volume   
 pre-surgery 42,2 cm3 
   
Steroids   
 received 34 (65%) 
 not received 18 (35%) 
   
MGMT status   
 methylated  17 (33%) 
 unmethylated 35 (67%) 
 
4.3  Morphologic characteristics of different MDSCs subsets 
For morphological analysis, cytospins were performed and cells were stained with 
hematoxylin and eosin. Representative pictures of the MDSC subsets are shown in 
Figure 10. CD14highCD15positive cells displayed typical features of monocytes with a 
lobulated or reniform nucleus usually eccentrically placed, and a grayish-blue 
cytoplasm. CD14lowCD15high cells revealed the typical morphology of neutrophils with 
segmented nuclei and pale pink cytoplasm. CD14lowCD15intermediate cells displayed 
features of eosinophils with a classic bilobed nucleus and eosinophilic cytoplasm 
filled with numerous red granules of uniform size. CD14lowCD15negative showed big 
round nuclei with a small basophilic cytoplasm characteristic for immature myeloid 
cells. 
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The flow cytometry evaluation of the different subsets of peripheral blood 
mononuclear cells and their expression intensity of CD14 and CD15 from blood 
obtained from patients with Glioblastoma is shown in Figure 11.GBM patients had an 
increased percentage of monocytic CD14highCD15positive MDSCs and neutrophilic 
CD14lowCD15high MDSCs in their peripheral blood when compared to healthy donors, 
whereas the percentage of immature CD14lowCD15negative MDSCs was significantly 
reduced. Moreover, a significant increase in the frequency of both monocytic 
CD14highCD15positive and neutrophilic CD14lowCD15positive MDSCs at the tumor site 
could be shown. 
 
Figure 10: Morphologic characteristics of different MDSC subsets in the peripheral blood of glioblastoma 
patients.-Myeloid cells were labeled with anti-CD11b and anti-CD14 antibodies and after sorting four 
major MDSC subpopulations were defined: CD14
high
CD15
positive
are further referred to as a monocytic 
phenotype, CD14
low
CD15
low
 MDSCs showed characteristics of immature myeloid cells and the 
CD14
low
CD15
positive
 granulocytic phenotype consisted of CD14
low
CD15
high
 neutrophils and 
CD14
low
CD15
intermediate
 eosinophils 
Figure 11: shows different subtype distributions of MDSCs in GBM patients. Healthy donors N=26, GBM N=52. 
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4.4  Distribution of different MDSCs subsets within PBMC and TILs of healthy 
donors (HD) and glioblastoma patients (GBM) 
Table9:  Distribution of different MDSCs subsets within PBMC and TILs of healthy donors (HD) and 
glioblastoma patients (GBM) 
Population PBMC-
HD 
PBMC-
GBM 
P-
value 
PBMC-
GBM 
TIL-
GBM 
P-value 
 % %  % %  
CD11bhigh 
%CD45 (w/o 
Lymph) 
      
Mean  53,21 56,62 0.5264 56,62 25,31 <0.0001 
Std. Deviation 25,92 20,44  20,44 14,88  
CD14highCD15pos       
Mean  3,420 9,668 0.0018 9,668 29,95 <0.0001 
Std. Deviation 4,464 11,95  11,95 18,24  
CD14lowCD15pos       
Mean 28,32 40,56 0.0339 40,56 48,47 0.1226 
Std. Deviation 24,75 28,65  28,65 19,84  
CD14lowCD15high       
Mean 13,61 27,06 0.0020 27,06 38,76 0.0029 
Std. Deviation 14,73 21,97  21,97 18,86  
CD14lowCD15int       
Mean 14,24 13,57 0.3930 13,57 9,753 0.4372 
Std. Deviation 13,08 17,39  17,39 11,35  
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CD14lowCD15neg       
Mean 22,71 3,891 <0.000
1 
3,891 2,223 0.0980 
Std. Deviation 19,22 5,425  5,425 2,715  
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4.5  Phenotypic analysis of MDSC subpopulation in peripheral blood and 
tumor 
To further investigate the phenotype of MDSC according to their expression profile, 
all four previously described MDSC subgroups were stained with HLA-DR, CD16 and 
CD124 antibodies as listed in the material and methods section.   
 
Figure12: Phenotypic analysis of monocytic, granulocytic, neutrophilic and eosinophilic MDSCs in 
peripheral blood (PBMC), tumor specimen (TIL) and healthy donors (HD) 
 
Figure 12 demonstrates that HLA-DR was significantly upregulated on the monocytic 
phenotype MDSCs from peripheral blood of glioblastoma patients when compared to 
healthy donors, whereas the granulocytic phenotype MDSCs remained negative for 
HLA-DR. In contrast, HLA-DR was significantly upregulated on both tumor-infiltrating 
monocytic and granulocytic MDSCs, mainly on the eosinophilic MDSCs subtype. 
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Moreover, a significant down-regulation of CD16 on tumor-infiltrating monocytic and 
granulocytic MDSCs could be shown, when compared to MDSCs in the peripheral 
blood of glioblastoma patients. Remarkably, up-regulation of CD124 (IL4Rα chain) 
was mainly restricted to tumor-infiltrating monocytic MDSCs. 
4.6 Influence of steroid ingestion and MGMT status on MDSCs subgroups 
 
Steroids are known immunosuppressant‘s and are widely used therapeutically. In 
terms of GBM the surrounding edema is usually responsible for the onset of 
neurological symptoms. The initial application of steroids improves the edema 
through a stabilisation of the blood brain barrier, but has no curative benefit. The 
influence of steroid ingestion on the presence of the different MDSCs subsets in the 
periphery cells as well as in the tumor was further investigated. Figure 13 shows the 
distribution of MDSCs comparing patients who received steroids (n=34) vs patients 
without steroid use (n=18). Interestingly the ingestion of steroids showed no 
significant difference for cells obtained from peripheral blood or tumor.   
 
 
Figure13: MDSC distribution in the tumor and peripheral blood with and without steroid ingestion 
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As previously described in the introduction, the MGMT promoter methylation status is 
an important marker in terms of chemotherapy response and overall survival. 
Therefore, the correlation between MGMT methylation status of the tumor and MDSC 
distribution in the tumor and peripheral blood was investigated. As displayed in 
Figure 14, we could not detect significant differences in the frequency of MDSC 
subsets in peripheral blood and tumors between MGMT methylated or unmethylated 
tumors.  
 
 
 
 
 
 
 
 
4.7.  DCFA and ARG1 expression of MDSC subpopulation in PBMCs and TILs 
in GBM 
We could demonstrate that MDSCs in patients with glioblastoma show a different 
expression profile of cell surface markers.Next, we examined the activation status of 
these cells. For our analysis, a general oxidative stress indicator dye DCFDAwas 
used. This fluorescent dye measures hydroxyl, peroxyl and other reactive species 
(ROS) activity within the cell. After diffusion into the cell, DCFDA is deacyetylated by 
cellular esterases to a non-fluorescent compound, which is later oxidized by ROS 
into DCF. DCF is highly fluorescent and can be detected with fluorescent 
spectroscopy at a maximum emission of 495nm. After staining the four subgroups of 
tumor and peripheral blood MDSCs according to the procedure described in the 
material and methods section the fluorescent analysis was performed and the result 
is shown in Figure 15. As displayed, all four subtypes of MDSCs produced ROS in 
both MDSC subsets, but mainly in peripheral blood.  
Figure 14:  MDSC distribution in the tumor and peripheral blood according to MGMT promoter 
methylation status . 
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Next, Arginase 1 expression of MDSCs was investigated. Arginin is essential for 
cytotoxic immune reaction of CTL cells and one of the proposed immunosuppressive 
mechanisms of MDSCs. It is hypothesised that MDSCs secrete Arginase,which 
degrades the amino acid Arginin. To study the role of TILs and PBMCs among 
MDSC in GBM patients Arginase 1 expression was studied with the 
Fixation/Permeabilization method described in the material and methods section. The 
intracellular staining for Arginase 1 is shown in Figure 15. Arginase 1 was strongly 
upregulatedin tumor-infiltrating MDSCs, predominantly in monocytic MDSCs, 
whereas only a minor fraction of MDSCs in peripheral blood expressed Arginase 1. 
This data demonstrates different intracellular up regulations of Arginase1 between 
MDSCs obtained from PBMCs and TILs. 
 
Figure15: Arginase 1 (Arg1+) and ROS (DCFA+) expression of the four different subtypes obtained from 
peripheral blood and tumor 
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4.8  T-Cell suppression assay of sorted MDSC subpopulations 
 
As MDSC seems to modulate the immunologic response of GBM patients, the next 
question was whether MDSCs suppress T-cell responses. Therefore, freshly 
prepared MDSCs from peripheral blood and tumor material of the same patient were 
sorted by flow cytometry and analyzed in an autologous non-specific T-cell 
proliferation assay. After co-cultivation of T-cells and MDSCs at a 2:1 ratio for 5 days, 
T-cells were harvested and labeled with the fluorescent dye CFSE. CFSE binds to 
any cellular protein with primary amines and during cell division the dye is distributed 
equally between daughter cells. This can be measured as successive halving of the 
fluorescence intensity of the dye. For FACS analysis of T-cells the anti-CD3 antibody 
was used. As shown in Figure 16, granulocytic, and mainly neutrophilic blood-derived 
MDSCs significantly reduced T-cell proliferation, whereas tumor-derived MDSCs did 
not suppress T-cell proliferation in vitro. The same pattern could be observed with 
CD14highCD15positive cells of monocytic phenotype. Representative dot plots of T cell 
proliferation and intracellular INF-γ secretion after addition of CD14lowCD15high 
neutrophilic MDSCs to CFSE-labeled autologous T-cells at different T-cell: MDSCs 
ratios (1:1 – 4:1) and PMA/ionomycin stimulation is shown in Figure 17. The 
percentage values represent the fraction of INF-γ secreting CSFE-labeled T-cells. 
 
Figure16: T-cell suppression assay with autologous CFSE-labeld T-cells and FACS-sorted MDSC subsets 
obtained from PBMC or tumor suspensions at a ratio of 2:1. 
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Figure17: Representative dot plots of T cell proliferation and intracellular INF-γ secretion after addition 
ofneutrophilic MDSCs to CFSE-labeled autologous T-cells and PMA/ionomycin stimulation 
 
4.9.  Frequency of MDSCs in the tumor is dependent on the pre-operative 
tumor volume 
 
To gain a deeper insight into the dynamics of MDSC attraction to the tumor site, 
correlations between the frequency of MDSC subsets in the tumor tissue and the 
tumor volume before resection was investigated. Therefore, the pre-operative tumor 
volume on MRI was calculated as described in the material and methods section and 
correlated to the proportion of MDSC subsets within the tissue obtained from tumor 
resection. Regression analysis showed that the frequency of granulocytic (p=0,0006), 
neutrophilic (p=0,0172) and eosinophilic (p=0,0066) MDSCs positively correlated with 
the tumor volume before resection, whereas a negative association between the 
frequency of monocytic (p=0,0060) and the tumor volume before resection was found 
(Figure 18).  For MDSCs obtained from peripheral blood no correlation between pre- 
and postoperative analysis could be found (data not shown). 
 
 
 
 
 
 
 
 
  4.Results   
44 
 
monocytic     granulocytic 
        
neutrophilic     eosinophilic 
 
 
 
Figure18: Correlation between the proportion of granulocytic, neutrophilic, eosinophilic and monocytic 
MDSCswithin TILs (n=52) and the tumor volume before tumor resection 
 
4.10  Correlation of MDSCs with Tregs in peripheral blood and tumor and time 
to tumor progression  
 
The mechanism by which Tregs limit anti-tumor immunity is not fully understood to 
date.Therefore, the correlation of Tregs andgranulocytic or monocytic TIL and PBMC 
subtypes of MDSCs was investigated next. As depicted in Figure 19,  significant 
correlation between theseMDSC subsets and tumor-infiltrating CD4+ T-cell regulatory 
T-cells could not be found.  
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Figure19:Correlation between the proportion of granulocytic and monocytic TIL and PBMC MDSCsand 
CD4 Treg (n=39).  
 
Next, the correlation between the presence of granulocytic and monocytic MDSCs 
and time to tumor progression was investigated (follow-up were only available for 28 
patients). Summarising, no relevant correlation between these MDSC subsets and 
time to progression was observed (Figure 20).  
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Spearman correlation 0,1012
P-value                       0,5454
monocytic granulocytic
monocytic granulocytic
Spearman correlation -0,2314
P-value                        0,1564
Spearman correlation 0,1937
P-value                       0,2373
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Figure20:Correlation between the proportion of monocytic (CD14
high
CD15
positive
) or granulocytic 
(CD14
low
CD15
positive
) TIL and PBMC MDSCs and the time to progression (n=28).  
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5.Discussion 
Myeloid-derived suppressor cells (MDSCs) comprise a heterogeneous population of 
myeloid cells, which are significantly expanded in cancer patients and are associated 
with tumor progression.  
This study gives a detailed characterization of the frequency, phenotype and 
suppressive function of distinct MDSC subsets in peripheral blood and tumor tissue 
of a large cohort of patients with primary glioblastoma. In peripheral blood, it could be 
shownthat both the proportion of CD14highCD15positivemonocytic and CD14lowCD15pos 
granulocytic MDSCs was significantly higher compared to healthy controls.  The 
majority of granulocytic MDSCs consisted of CD14lowCD15positive  neutrophilic 
MDSCs. 
In the tumor, a large proportion of CD14lowCD15positive granulocytic MDSCswas found, 
that mainly consisted of neutrophilic CD14lowCD15high MDSCs, but also an increased 
amount of CD14highCD15positive monocytic MDSCs. These findings are supported by 
recently published data from Raychaudhuri et al. who observed a predominance of 
granulocytic (CD15positiveCD14negative) over monocytic (CD15negativeCD14positive) MDSCs 
in tumor specimens of glioblastoma patients [41]. 
It was also analyzed whether the MGMT methylation status of the tumor or the use of 
corticosteroids influenced the frequency of MDSC subsets in blood and tumors, but 
we could not detect significant differences between tumors with an unmethylated or 
methylated MGMT status or steroid users and non-users in our large patient cohort. 
Noteworthy, the time of steroid ingestion before tumor resection was not analyzed. 
This could be a confounding factor since steroids could influence the MDSC 
frequency and phenotype. 
Interestingly, the relative frequency of MDSC subsets was dependent on the tumor 
volume before resection with higher proportions of granulocytic MDSCs in larger 
tumors, whereas higher proportions of monocytic MDSCs were present in smaller 
tumors. Reasons for the positive correlation between tumor volume and MDSCs 
amount could be that a proportionally higher amount of tissue necrosis and hypoxia 
increases the production of chemo-attractants. The predomination of granulocytic 
MDSC within the tumor could be due to a selective chemokine-receptor expression 
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on different MDSCs subtypes. In thiscontext, it would not only be interesting to 
analyze which chemokines are predominantly produced by glioblastomas depending 
on the tumor size, but also to get more information about the spatiotemporal 
distribution of these cells within the tumor. In a murine model, Sawanobori et al. 
showed that tumor-infiltrating neutrophils accumulate near the center of the tumor, 
whereas ARG1-expressing macrophages were distributed throughout the tumor 
mass [42].After infiltrating into glioblastoma tissue, MDSCs are strongly modified by 
the tumor microenvironment. It could be seen that both granulocytic and monocytic 
MDSCs showed an activated phenotype with downregulation of CD16 and 
upregulation of HLA-DR, most prominent in monocytic MDSCs. While eosinophilic 
MDSCs also revealed strong upregulation of HLA-DR, neutrophilic MDSCs displayed 
a diverse HLA-DR expression pattern. Further subanalysis showed that HLA-DRlow/- 
neutrophilic MDSCs were CD16positive, expressed CD124 and were Arginase I 
positive, whereas HLA-DRpositive neutrophilic MDSCs were CD16negative, did not 
express CD124 and were Arginase I negative (data not shown). This also suggests 
that there is an enormous plasticity within the granulocytic fraction of MDSCs within 
glioblastomas. Monocytic MDSCs were strongly positive for CD124 and Arginase I, in 
contrast to their counterparts in peripheral blood.These cells also strongly expressed 
CD206 and the GM-CSF receptor (data not shown) and thus might correspond to the 
population of previously described tumor-associated macrophages (TAM) displaying 
a M2 phenotype [43]. Recently, Kohanbash et al. showed that CD124 mediates the 
IL-13-induced production of Arginase within bone marrow-derived myeloid cells 
which suppressed T-cell proliferation in an IL-4Rα-dependent manner [44]. They also 
identified a fraction of CD33+CD14+HLADR- cells within glioblastomas that expressed 
CD124 and suppressed the proliferation of autologous CD8+ T-cells. 
This study also adds insight into the contribution of different MDSC subsets to the 
inhibition of T-cell activity in peripheral blood and tumor tissue. It could beobserved 
that mainly freshly isolated blood-derived neutrophilic and less effectively eosinophilic 
MDSCs, but not monocytic MDSCs were able to suppress autologous non-specific T-
cell proliferation and IFN-γ secretion in vitro. This is in accordance with previous 
reports demonstrating that peripheral cellular immunosuppression in patients with 
glioblastoma is mediated by degranulated neutrophils  or CD33+CD15+ cells [27, 45]. 
Altogether, these results clearly demonstrate that granulocytic MDSCs are the 
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functionally immunosuppressive subset in the blood of glioblastoma patients. In 
contrast, freshly isolated tumor-derived MDSCs did not show T-cell inhibitory 
capacities in our standard T-cell suppression assay. Similar observations have been 
made by Gros et al. in patients with metastatic melanoma [46]. They speculated that 
HLA-DR expression on MDSCs distinguishes T-cell suppressive from non-
suppressive cells. Our preliminary experiments with anti-HLA blocking monoclonal 
antibodies did not lead to different results suggesting that HLA-DR expression is not 
a decisive factor (data not shown). Although it is shown thattumor-derived MDSCs 
express significant amounts of Arginase I, our findings do not rule out that tumor-
derived MDSCs are able to suppress T-cell functions in vivo, because our T-cell 
suppression assay with a coculture time of more than 96 hours might not reflect the 
immediate suppressive capacity of tumor-derived MDSCs or tumor-specific co-factors 
that are essential for the release of Arginase I containing granules from tumor-
derived MDSCs into the culture supernatant are missing [47]. Finally, it could not be 
fully excluded that the isolation procedure of MDSCs from tumor tissue affects their 
suppressive capacity subsequently in vitro analysis. 
As regulatory T-cells (Treg) play an important role in GBM-induced 
immunosuppression, it was interestingto see whether there was a relationship 
between MDSCs subsets and Treg at the tumor site. As shown in Figure 19. 
significant correlations between MDSC subsets and tumor-infiltrating Treg could not 
be found.However, this finding does not rule out the possible interaction between 
other T-cell subpopulations and their functioning inside tumor microenvironment. 
Finally, it was investigated whether there was a positive association between the 
frequency of different MDSC subsets in peripheral blood or tumor tissue and the time 
of tumor progression of glioblastoma. Nosignificant correlation was  found between 
the frequency of different MDSC subsets and time to tumor progression (TTP). This 
could be explained by the heterogeneity of the tumors and different responses to 
subsequent  radiation and chemotherapy.  
In summary, this thesis has several clinical implications for immune-based 
interventions in glioblastomas. First, as the tumor size strongly correlates with the 
accumulation of MDSCs at the tumor site, tumor reduction should be as good as 
possible to achieve a minimal residual disease status which is one of the 
prerequisites for an effective immunotherapy [48]. Secondly, strategies to target 
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MDSCs in peripheral blood and tumor tissue should be implemented into 
immunotherapeutic approaches, because MDSCs comprise the most prominent cell 
type with immunosuppressive functions in peripheral blood and tumor tissue of 
glioblastomas. Several compounds including conventional chemotherapeutic drugs 
have been identified that can influence MDSCs at different levels of [49]. 
These findings give new insight into the immunobiology of GBM, providing a detailed 
characterization of the nature and suppressive function of MDSCs in GBM patients 
and its clinical implication for immune based interventions in glioblastomas. First, 
granulocytic MDSCs in peripheral blood and tumor tissue should be carefully 
monitored during immunotherapeutic studies in glioblastoma patients. Second, 
strategies to target MDSCs in peripheral blood and tumor tissue should be 
implemented into immunotherapeutic approaches, because MDSCs comprise the 
most prominent cell types with immunosuppressive functions in peripheral blood and 
tumor tissue of glioblastoma patients. 
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6. Summary 
Myeloid-derived suppressor cells (MDSCs) comprise a heterogeneous population of 
myeloid cells that are significantly expanded in cancer patients and are associated 
with tumor progression. Multicolor flow cytometry was used to study the frequency, 
phenotype, and function of MDSCs in peripheral blood and freshly resected tumors of 
52 participants with primary glioblastoma (GBM). The frequency of 
CD14highCD15positive monocytic and CD14lowCD15positive granulocytic MDSCs was 
significantly higher in peripheral blood of GBM participants compared with healthy 
donors. The majority of granulocytic MDSCs consisted of 
CD14lowCD15high neutrophilic MDSCs with high T-cell suppressive capacities. At the 
tumor side, an increase in CD14highCD15positive monocytic MDSCs and high 
frequencies of CD14lowCD15positive granulocytic MDSCs was found, that displayed an 
activated phenotype with downregulation of CD16 and upregulation of HLA-DR 
molecules, which did not inhibit T-cell proliferative responses in vitro. 
Surprisingly neither the MGMT methylation status of the tumor tissue nor the use of 
steroids did influence the frequency of MDSC subsets in peripheral blood and 
tumors. Interestingly, the relative frequency of both MDSC subsets was dependent 
on the tumor volume before resection with higher proportions of granulocytic MDCs 
in larger tumors, whereas higher proportions of monocytic MDCs were present in 
smaller tumors. This thesis provide a detailed characterization of different MDSC 
subsets in GBM patients and indicate that both granulocytic MDSCs in peripheral 
blood and at the tumor site play a major role in GBM-induced T-cell suppression. 
 
 
 
 
 
 
  7. Zusammenfassung   
52 
 
7. Zusammenfassung 
Myeloiden Suppressorzellen (MDSC) wird eine zentrale Rolle bei der 
Immunsppression in malignen Gliomen zugeschrieben. In der vorliegenden Arbeit 
wurde die Frequenz, der Phänotyp und die suppressive Funktion von MDSC im 
peripheren Blut und im Tumorgewebe von insgesamt 52 Patienten untersucht. 
Die Analyse zeigte, dass der Anteil an CD14highCD15positive (monozytärer Phänotyp) 
und der  CD14lowCD15positive (granulozytärer Phänotyp) MDSCs im peripheren Blut 
von Glioblastompatienten im Vergleich zu Kontrollpersonen stark erhöht ist. Die 
Mehrheit des granulozytären Phänotyps besteht aus CD14lowCD15high (Neutrophiler 
Phenotyp) MDSCs, die eine hohe Immunosuppressivität aufzeigten.  
Im Tumorgewebe konnte eine Erhöhung der CD14highCD15positive MDSCs sowie der 
CD14lowCD15positive MDSCs nachgewiesen werden. Desweiteren zeigte sich eine 
Herrunterregulierung von CD16 und einer Aufregulierung von HLA-DR der MDSCs 
im Tumorgewebe, welche auf einen aktivierten Phenotypen 
hindeutete.Bemerkenswerterweise korrelierte weder der MGMT Promotor-
Methylierungsstatus noch die Einnahme von Steroiden mit dem Auftreten der 
Häufigkeit von MDSCs im periphären Blut noch im Tumorgewebe. Darüber hinaus 
konnte eine höheres Auftreten von granulozytären MDSCs in Tumoren größeren 
Volumens nachgewiesen werden, wo hingegen Tumore kleineren Volumens einen 
höheren Anteil an monozytären MDSCs aufzeigten. Die hier vorliegende Arbeit zeigt 
eine ausführliche Charakterisierung der verschiedenen MDSC Subtypen in 
Glioblastompatienten. Es konnte gezeigt werden,  dass dem granulozytären MDSC 
Phänotyp sowohl im Blut als auch im Tumorgewebe die führende Rolle in der MDSC 
induzierten T-Zell Immunosuppression zukommt. 
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